Fortress Biotech Inc. (NASDAQ:FBIO) currently has a daily average trading volume of 694.19K but it saw 1016286 shares traded on Thursday. With a market cap of 63.58M USD, stock’s current market price of $0.49 came falling about -4.03 while comparing to the previous closing price of $0.51. In past 52 weeks, the stock remained buoying in the range of price level as high as $1.33 and as low as $0.48. In the recent trading on the day, stock has struck highest price mark of $0.51 while lowest mark touched by it was $0.489.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Taking a look at 20-day trading activity of Fortress Biotech Inc. (FBIO) gives us an average price of $0.6652, while its current price level is -62.95% below from 52-week high level whereas it is 2.23% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.7163 while that of 200 days or SMA-200 reads an average of $0.8054. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.98% during that period while stretching the period over a month that increases to 7.81%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 23.76 which implies that the stock is in oversold territory.
Fortress Biotech Inc. (FBIO)’s stock is currently under the radar of 6 analysts who are in consensus at a 12-month price target range of between $2.25 and $24.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $2.25 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $24.00. Average price target assigned by them is $7.58 which highlights an upside potential of 93.54% for the stock over that period. And to attain the median price target of $5.00 assigned by those analysts, stock has to add about 90.2% of value to its current levels.
Data by FactSet Research shows that 6 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 6 analysts suggested the investors to Buy the stock while 0 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Strong Buy.
Over the week, FBIO’s stock price is moving -4.10% down while it is -32.76% when we observe its performance for the past one month. Year-to-date it is -25.05% down and over the past year, the stock is showing a downside performance of -41.30%.
The latest quarterly earnings report issued by the company was for quarter ended 3/30/2023, when its quarterly earnings per share (EPS) of -$0.21 beaten by the consensus estimate of -$0.2 for the same. The company is expected to be releasing its next quarterly report in 08/10/2023, for which analysts forecasted an EPS of -$0.19 while estimate for next year EPS is -$0.7. For FBIO, analysts are forecasting an EPS-growth rate of 27.80% for current year and estimate for EPS growth in next year is 75.70%. In next quarter, company is expected to be making quarterly sales of $24.52 million as analysts are expecting the sales for current fiscal year at $87.71 million and seeing the company making $169.18 million in sales next year. Moreover, analysts are in estimates of $19.58 million for current-quarter revenue.
Currently, Fortress Biotech Inc.’s total number of outstanding shares is 101.89M with 31.08% of that held by the insiders while 24.70% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -143.70% and return on equity (ROE) at -169.10%. Stock’s beta reads 2.04. Stock has a price to book (P/B) ratio of 1.33 while price to sale or P/S ratio amounts to 0.99. Its return on asset (ROA) is -29.70% on average.
